ImmunityBio, Inc. (IBRX) — Stock Score Summary

ImmunityBio, Inc. (IBRX) has a MoatMap StockRank of 63/100 based on Quality (32/100), Value (47/100), and Momentum (68/100) factor scores. The current signal is HOLD. ImmunityBio is a highly speculative clinical-stage biotech company with massive cash burn and high debt. This completely violates the Terry Smith lens of owning profitable, high-ROIC, asset-light compounders.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing a broad pipeline of off-the-shelf natural killer (NK) cell therapies and other immunotherapies for cancer and infectious diseases. The company's proprietary NantCancerVax platform aims to activate multiple arms of the immune system to achieve durable responses. Its innovative approach and diverse development programs position it as a potential disruptor in oncology and immunology.

Key Financial Metrics

Price$7.25
Market Cap$8.1B
P/E (Forward)121.50
Price/Book-8.77
Return on Invested Capital-54.3%
Gross Margin99.3%
Operating Margin-157.9%
Revenue Growth167.6%
Free Cash Flow$-194M

ImmunityBio, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is ImmunityBio, Inc.’s (IBRX) StockRank?
MoatMap’s StockRank for ImmunityBio, Inc. (IBRX) is 63/100, with a Hold signal. It is a composite of Quality (32), Value (47), and Momentum (68) factor ranks across MoatMap’s 19,000+ stock universe.
Does ImmunityBio, Inc. have an economic moat?
ImmunityBio, Inc. (IBRX) has a Quality factor score of 32/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is ImmunityBio, Inc. a buy, hold, or sell?
MoatMap’s current signal for ImmunityBio, Inc. (IBRX) is Hold, based on a StockRank of 63/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is ImmunityBio, Inc. in?
ImmunityBio, Inc. (IBRX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksIBRX deep dive reportAI ChampionsHow we score stocksSense-check another stock